Merck finally rolls out sleep aid Belsomra after FDA roadblocks

Merck's ($MRK) long-awaited insomnia drug Belsomra (suvorexant) has now hit pharmacy shelves in the U.S. The drug is a first-in-class sleep aid finally approved last year after an initial rejection by the FDA. Early analyst estimates had put 2017 sales at more than $500 million, but after the agency chose to approve a lower dose than hoped for, those forecasts fell to about $300 million. Release

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.